Alto Neuroscience (ANRO) Competitors $4.16 +0.23 (+5.71%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. FULC, ABEO, CAPR, ZYBT, ADCT, BNTC, FDMT, INBX, CADL, and LRMRShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Its Competitors Fulcrum Therapeutics Abeona Therapeutics Capricor Therapeutics Zhengye Biotechnology ADC Therapeutics Benitec Biopharma 4D Molecular Therapeutics Inhibrx Biosciences Candel Therapeutics Larimar Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Is FULC or ANRO more profitable? Fulcrum Therapeutics' return on equity of -31.05% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -31.05% -28.96% Alto Neuroscience N/A -44.34%-36.73% Do institutionals & insiders believe in FULC or ANRO? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, FULC or ANRO? Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum TherapeuticsN/AN/A-$9.73M-$1.22-5.34Alto NeuroscienceN/AN/A-$61.43M-$2.39-1.74 Which has more risk and volatility, FULC or ANRO? Fulcrum Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Does the media prefer FULC or ANRO? In the previous week, Alto Neuroscience had 35 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 40 mentions for Alto Neuroscience and 5 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.96 beat Alto Neuroscience's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 2 Very Positive mention(s) 3 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend FULC or ANRO? Fulcrum Therapeutics currently has a consensus price target of $7.57, indicating a potential upside of 16.13%. Alto Neuroscience has a consensus price target of $8.50, indicating a potential upside of 104.08%. Given Alto Neuroscience's higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryFulcrum Therapeutics beats Alto Neuroscience on 10 of the 13 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeuroscienceMED IndustryMedical SectorNYSE ExchangeMarket Cap$113.47M$3.09B$5.74B$21.13BDividend YieldN/A2.24%4.40%3.54%P/E Ratio-1.7520.6830.4129.01Price / SalesN/A346.97429.2971.83Price / CashN/A43.2325.7818.23Price / Book0.749.749.644.71Net Income-$61.43M-$54.08M$3.27B$995.89M7 Day Performance20.55%4.64%3.69%2.43%1 Month Performance35.23%3.27%3.57%2.68%1 Year Performance-64.19%7.34%30.83%10.89% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience2.1044 of 5 stars$4.17+5.7%$8.50+104.1%-65.6%$113.47MN/A-1.75N/AFULCFulcrum Therapeutics1.0229 of 5 stars$6.64-2.6%$7.57+14.0%-30.1%$368.90M$80M-5.44100ABEOAbeona Therapeutics4.4093 of 5 stars$6.91-3.1%$19.50+182.2%+27.1%$364.75M$400K9.8790CAPRCapricor Therapeutics3.0502 of 5 stars$7.70-3.3%$22.56+192.9%+44.7%$363.91M$13.39M-4.70101ZYBTZhengye BiotechnologyN/A$7.84+4.4%N/AN/A$354.22M$25.53M0.00278ADCTADC Therapeutics1.4014 of 5 stars$3.24+3.5%$7.75+139.2%+0.5%$352.12M$70.84M-2.06310High Trading VolumeBNTCBenitec Biopharma1.3695 of 5 stars$12.71-2.3%$26.00+104.6%+46.0%$341.51MN/A-8.4220FDMT4D Molecular Therapeutics1.7222 of 5 stars$7.27+0.1%$30.40+318.2%-54.9%$339.06M$40K-2.06120INBXInhibrx Biosciences1.6426 of 5 stars$23.87+2.3%N/A+87.7%$337.95M$200K-2.26166News CoveragePositive NewsCADLCandel Therapeutics2.1677 of 5 stars$5.96-2.1%$22.00+269.1%+0.5%$334.31M$120K-8.6460LRMRLarimar Therapeutics2.566 of 5 stars$3.90-2.7%$18.43+372.5%-52.7%$331.94MN/A-2.5030 Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors Abeona Therapeutics Competitors Capricor Therapeutics Competitors Zhengye Biotechnology Competitors ADC Therapeutics Competitors Benitec Biopharma Competitors 4D Molecular Therapeutics Competitors Inhibrx Biosciences Competitors Candel Therapeutics Competitors Larimar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredSell this, buy thatI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access